View |
|
BR-1276
|
Human Albumin
|
Alburx
|
250 g/L (25 % w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
Automatic Renewal
|
05 January 2023
|
07 June 2028
|
View |
|
BR-1277
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
BR-1277
|
03 January 2023
|
07 June 2028
|
View |
|
BR-1278
|
Human Albumin
|
Alburx
|
250 g/L (25% w/v)
|
Solution for Intravenous Infusion
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
BR-1278
|
31 December 2022
|
07 June 2028
|
View |
|
BR-1279
|
Etanercept
|
Etveza 25
|
25mg
|
Lyophilized Powder for Subcutaneous Injection
|
Immunosuppressant/ Tumor
Necrosis Factor Alpha Inhibitor
|
Shangpai CP Guojian Pharmaceutical Co., Ltd
|
China
|
Initial (Compliance)
|
19 November 2019
|
11 July 2024
|
View |
|
BR-1280
|
Atezolizumab
|
Tecentriq
|
60 mg/mL (1.2 g/20 mL)
|
Concentrate for Solution for
Infusion
|
-
|
Roche Diagnostics GmbH
|
Germany
|
Monitored Release (Variation)
|
22 February 2023
|
22 February 2028
|
View |
|
BR-1282
|
Eptacog alfa activated
|
NovoSeven RT
|
1 mg/vial (50KIU/vial)
|
Powder And Solvent For Solution For Injection
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
01 August 2023
|
25 July 2028
|
View |
|
BR-1284
|
Isophane Insulin (Recombinant DNA)
|
Humulin N
|
100 Units/mL
|
Suspension for Injection (SC)
|
-
|
Lilly France S.A.S.
|
France
|
Renewal
|
11 October 2022
|
31 October 2027
|
View |
BR-1287_PI_01.pdf
|
BR-1287
|
Ustekinumab
|
Stelara
|
45mg/ 0.5mL
|
Solution for Injection
|
-
|
Cilag AG
|
Switzerland
|
-
|
10 May 2019
|
10 May 2024
|
View |
|
BR-1289
|
Rotavirus Vaccine (Live, Attenuated)
|
Rotasiil
|
Formulation: After reconstitution, each dose (2.5 mL) contains:
Live Attenuated Bovine-Human Rotavirus Reassortant [G1, G2, G3, G4 and G9]* >10^5.6 FFU/Serotype *Grown on vero cells
|
Freeze-dried Powder for Oral Suspension
|
-
|
Serum Institute of India Private Limited
|
India
|
-
|
18 March 2022
|
08 February 2027
|
View |
|
BR-1290
|
Inactivated Poliomyelitis Vaccine (Types 1, 2 And 3)
|
Poliovac
|
0.5 mL
|
Suspension For Injection (IM/SC)
|
-
|
Serum Institute of India Private Limited
|
India
|
Initial (Variation)
|
09 February 2023
|
09 February 2028
|
View |
BR-1291_PI_01.pdf
|
BR-1291
|
Liraglutide
|
SAXENDA
|
6mg/ mL
|
Solution for Injection
|
Anti-Obesity
|
NOVO NORDISK A/S
|
Denmark
|
Monitored Release
|
25 April 2019
|
25 April 2025
|
View |
|
BR-1292
|
Rabies Vaccine Inactivated (Freeze Dried)
|
Rabivax-S
|
each dose contains nlt 2.5 IU
|
Solution For Intradermal Injection
|
-
|
Serum Institute of India
|
India
|
-
|
06 May 2019
|
06 May 2024
|
View |
|
BR-1293
|
Rituximab
|
Rituxikal (50)
|
500 mg/ 50 mL
|
Concentrate for Solution for Infusion
|
-
|
Sinergium Biotech S.A.
|
Argentina
|
-
|
24 May 2019
|
24 May 2024
|
View |
|
BR-1294
|
Rituximab
|
Rituxikal
|
100 mg/ 10 mL
|
Concentrate for Solution for Infusion
|
-
|
Sinergium Biotech S.A.
|
Argentina
|
-
|
24 May 2019
|
24 May 2024
|
View |
|
BR-1296
|
Dulaglutide
|
Trulicity
|
0.75 mg/0.5 mL
|
Solution For Injection
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
View |
BR-1297_PI_01.pdf
|
BR-1297
|
Dulaglutide
|
Trulicity
|
1.5 mg/0.5 mL
|
Solution For Injection
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
View |
BR-1298_PI_01.pdf
|
BR-1298
|
Ramucirumab
|
Cyramza
|
10 mg/mL
|
Concentrate For Solution For Infusion (IV)
|
-
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
02 July 2024
|
View |
BR-1299_PI_01.pdf
|
BR-1299
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
-
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
08 July 2024
|
View |
BR-1300_PI_01.pdf
|
BR-1300
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
-
|
Eli Lilly & Company
|
United States of America
|
Monitored Release
|
17 March 2022
|
08 July 2024
|
View |
BR-1301_PI_01.pdf
|
BR-1301
|
Daratumumab
|
Darzalex
|
20 mg/mL
|
Concentrate For Solution For Infusion (Iv)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
-
|
01 August 2019
|
01 August 2024
|